Last reviewed · How we verify
AGN-210961 Formulation 6
AGN-210961 is a selective androgen receptor modulator (SARM) designed to provide tissue-selective androgenic effects.
AGN-210961 is a selective androgen receptor modulator (SARM) designed to provide tissue-selective androgenic effects. Used for Muscle wasting or sarcopenia (investigational), Bone health / osteoporosis (investigational).
At a glance
| Generic name | AGN-210961 Formulation 6 |
|---|---|
| Sponsor | Allergan |
| Drug class | Selective androgen receptor modulator (SARM) |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Musculoskeletal |
| Phase | Phase 2 |
Mechanism of action
SARMs like AGN-210961 bind to androgen receptors with selectivity for certain tissues, aiming to deliver anabolic benefits (muscle, bone) while minimizing unwanted androgenic side effects in other tissues. This tissue selectivity is intended to improve the therapeutic window compared to traditional androgens or non-selective compounds.
Approved indications
- Muscle wasting or sarcopenia (investigational)
- Bone health / osteoporosis (investigational)
Common side effects
- Testosterone suppression
- Liver enzyme elevation
- Lipid profile changes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGN-210961 Formulation 6 CI brief — competitive landscape report
- AGN-210961 Formulation 6 updates RSS · CI watch RSS
- Allergan portfolio CI